Aminophylline Shows Short-Term Benefits in Asphyxiated Newborns, but Fails to Prevent Acute Kidney Injury: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-01-03 15:30 GMT   |   Update On 2025-01-03 15:30 GMT

India: A recent randomized open-label controlled trial has explored the potential benefits of aminophylline in preventing acute kidney injury (AKI) in term neonates suffering from severe perinatal asphyxia.

The study published in the Journal of Tropical Pediatrics revealed that administering a single dose of aminophylline (5 mg/kg) within the first hour of life to severely asphyxiated term neonates may temporarily boost urine output. However, it does not significantly reduce the overall incidence of AKI.

Acute kidney injury is a significant concern for neonates who experience severe perinatal asphyxia, as it can lead to long-term complications and increased mortality rates. The effectiveness of aminophylline in preventing or mitigating renal dysfunction in these neonates remains a topic of debate. In light of this, Arindam Ghosh, Department of Neonatology, Medical College and Hospital, Kolkata, West Bengal, India, and colleagues set out to investigate whether aminophylline, as adjunctive therapy, is more effective than standard care alone in preventing acute kidney injury in severely asphyxiated term neonates. Additionally, the study aimed to assess changes in other renal parameters associated with this treatment.

For this purpose, the researchers conducted an open-label randomized clinical trial involving term neonates with severe asphyxia (n = 41). These infants received an intravenous dose of aminophylline at 5 mg/kg within the first hour after birth, alongside standard care for birth asphyxia. The control group (n = 40) received standard care alone.

The study monitored and compared various parameters, including daily urine output, weight, serum creatinine levels, renal function status, and complications during the first five days of life. Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 25.

Key observations from the study are as follows:

  • Approximately 24.39% of neonates in the aminophylline group developed acute kidney injury, compared to 35.0% in the control group.
  • While urine output was generally higher in the aminophylline-treated newborns than in those receiving standard care, this difference did not reach statistical significance.
  • The most pronounced variations in urine output were noted on the second and third postnatal days.
  • The changes in plasma creatinine levels between the two groups during this period were also not statistically significant.

"Based on our study findings, we recommend that aminophylline therapy in this context should be restricted to research settings and not employed as a preventive measure," the researchers concluded.

Reference:

Munian, D., Dutta, S., Ghosh, A., & Saha, R. (2024). Role of aminophylline in prevention of acute kidney injury in term neonates with severe perinatal asphyxia: A randomized open-label controlled trial. Journal of Tropical Pediatrics, 70(6). https://doi.org/10.1093/tropej/fmae036


Tags:    
Article Source : Journal of Tropical Pediatrics

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News